De Motu Cordis (DMC) receives a letter of support from Food Allergy Research and Education (FARE)By dev|2026-08-17T05:11:45+00:00November 1, 2024|Categories: News|Read More 0
De Motu Cordis (DMC) Applauds ARS Pharma’s FDA Approval of Neffy®, Expanding Patient Options to Needle-Free Epinephrine Delivery and Inspiring Confidence in Our Own Development Efforts.By dev|2026-08-17T05:11:46+00:00August 16, 2024|Categories: News|Read More 0
De Motu Cordis (DMC) announces plans for the next stage of development for DMC-IH1, an inhaled epinephrine drug device combination productBy dev|2026-08-17T05:11:47+00:00July 17, 2024|Categories: News|Read More 0
Forbes magazine features DMC founder – how Professor John Fraser aims to ensure that through innovation, patients thrive, not just surviveBy dev|2026-08-17T05:11:48+00:00March 6, 2024|Categories: News|Read More 0
DMC Director, Doctor Glen Richards, a 2023 UQ Alumni Award winner!By dev|2026-08-17T05:11:49+00:00November 6, 2023|Categories: News|Read More 0
De Motu Cordis (DMC) welcomed Queensland Treasurer and Minister for Trade and Investment Honourable Cameron Dick MPBy dev|2026-08-17T05:11:50+00:00April 4, 2023|Categories: News|Read More 0
Press Release 27 February 2023By dev|2026-08-17T05:11:51+00:00February 27, 2023|Categories: News|Read More 0
